AKT1 and breast cancer: However, in endocrine‐resistant breast cancer, STING agonist monotherapy failed to active the STING signaling, due to the positive feedback of inactivated STING signaling and hyperactivated AKT1 strengthening the suppression of cGAS‐STING pathway by AKT1.